Researchers developed new migraine drug to prevent them in the initial stages. Some clinical trials are happening to launch soon into market.
Migraine attacks can cause significant pain for hours to days and can be so severe that the pain is disabling. Symptoms known as aura may occur before or with the headache.
These can include flashes of light, blind spots, or tingling on one side of the face or in your arm or leg.
The scientist with several experiments they found out Migraine drug known as Erenumab. A designed lab-version protein monoclonal antibody induced into body by injection. It affects the specific compounds that generate the migraine. The study authors reported to New England Journal of Medicine
The research on Migraine drug Erenumab was carried out by researchers from King’s College Hospital in the UK. The Universitätsmedizin Berlin in Germany, St Göran Hospital in Sweden, the Medical University of Innsbruck in Austria, Mercy Research, and the pharmaceutical company Amgen in the US.
Migraine Drug disables a protein known as calcitonin
The new Migraine drugs use special antibodies to moderate a system in the brain that cause pain. The effect is a bit like soundproofing, says Stephen Silberstein, a study author and director of the Jefferson Headache Center in Philadelphia. The US Food and Drug Administration and the European Medicines Agency are both expected to review the drugs sometime in the next several months.
Migraine drug disables a protein known as calcitonin gene-related peptide. Previous research found this protein may play a part in migraine symptoms. A second drug works in similar way, Fremanezumab also tested.
The study included 955 patients, divided into three groups, the first received 70 mg of Erenumab. The second got 140 mg dose of Migraine drug, and the last given a placebo. Both dosages seemed to work. The study reports that 43.3% of the 70-mg group and 50% of of 140-mg Erenumab group saw their monthly migraines drop about 50%.
The second trial reported for Fremanezumab, another Migraine drug an monoclonal antibody, similar erenumab, but targeting a different potential cause of migraines. That study involved 1,130 patients, also split into three groups over a 12-month period. Meanwhile, researchers gave quarterly doses of the protein treatment to the first group. Monthly doses to the second, and a placebo to the third. Both treatment schedules seemed to work in reducing migraines by 50%.
Moreover, Amgen and Novartis, the co-developers of Migraine drug, funded the trial, while Amgen also supplied the drug and conducted the data analyses.
